Novartis India Share Price

Isomorphic Labs has announced partnerships with major pharmaceutical firms,including Eli Lilly & Co. and Novartis AG

• Business Line
• 2 weeks 4 days ago

Pharmaceuticals company Novartis India announced Q4FY26 & FY26 results Financial Highlights: Revenue from operations for Q4FY26 stood at Rs 905.5 million, representing a growth of 5.41% QoQ from Rs 859.0 million in Q3FY26 and a 7.95% increase YoY compared to Rs 838.8 million in Q4FY25. Total Income for Q4FY26 was Rs 1,005.6 million, showing an increase of 6.24% QoQ from Rs 946.5 million and a 6.40% increase YoY from Rs 945.1 million. Profit after tax for Q4FY26 was Rs 252.5 million, reflecting a significant growth of 56.93% QoQ from Rs 160.9 million, but a decline of 13.82% YoY compared to Rs 293.0 million in Q4FY25. For FY26, Revenue from operations reached Rs 3,543.3 million, marking a marginal decline of 0.54% compared to Rs 3,562.7 million in FY25. Annual Total Income for FY26 stood at Rs 3,931.0 million, compared to Rs 3,982.3 million in the previous year. The annual Net Profit for FY26 was Rs 931.8 million, representing a decrease of 7.65% YoY from Rs 1,009.0 million in FY25. Total Comprehensive Income for the year FY26 was Rs 946.0 million, compared to Rs 1,018.7 million in FY25. Earnings Per Share (Basic & Diluted) for FY26 was Rs 37.74, compared to Rs 40.87 in the previous year. Business Highlights: Segment Performance: The company operates in a single operating segment, namely the "Pharmaceutical Business." During the year ended March 31, 2026, the company generated revenue of Rs 1,461.7 million from a single customer, which accounted for more than 10% of total revenue. Share Purchase Agreement: On February 19, 2026, the promoter, Novartis AG, entered into an agreement (SPA) to sell its entire 70.68% stake in the company (1,74,50,680 fully paid-up equity shares) to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. Dividend: The Board of Directors has recommended a dividend of Rs Nil per share (face value of Rs 5 each) for the financial year 2025-26, compared to Rs 25 per share in FY25. Labour Code Impact: The company assessed the incremental impact of the new Labour Codes, resulting in an increase in the provision for employee benefits by Rs 11.4 million (comprising Rs 7.9 million for Gratuity and Rs 3.5 million for leave benefits). Subsidiaries: As per Note 10, the company does not have any subsidiary, associate, or joint venture entities for the current reporting period. Result PDF

• Trendlyne
• 2 weeks 5 days ago

In October, Novartis agreed to acquire Avidity to enhance its focus on innovative drugs in heart, kidney, metabolic, immunology, neuroscience, and oncology

• Business Line
• 2 months 2 weeks ago